GATA6 expression in Barrett's oesophagus and oesophageal adenocarcinoma

Digestive and Liver Disease

Volumn 47, Issue 1, 2015, Pages 73-80

  Pavlov, Kirill ^a   Honing, Judith ^a   Meijer, Coby ^a   Boersma van Ek, Wytske ^a   Peters, Frans T M ^a   van den Berg, Anke ^a   Karrenbeld, Arend ^a   Plukker, John T M ^a   Kruyt, Frank A E ^a   Kleibeuker, Jan H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Barrett's oesophagus; GATA6; Oesophageal adenocarcinoma

Indexed keywords

TRANSCRIPTION FACTOR GATA 6; GATA6 PROTEIN, HUMAN;

ADULT; ARTICLE; BARRETT ESOPHAGUS; CANCER PROGNOSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS DYSPLASIA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MALIGNANT TRANSFORMATION; OVERALL SURVIVAL; PROTEIN EXPRESSION; SQUAMOUS EPITHELIUM; TISSUE MICROARRAY; ADENOCARCINOMA; AGED; CANCER STAGING; COHORT ANALYSIS; ESOPHAGEAL NEOPLASMS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY;

ADENOCARCINOMA; AGED; BARRETT ESOPHAGUS; COHORT STUDIES; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; FEMALE; GATA6 TRANSCRIPTION FACTOR; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 84919841566     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2014.09.014     Document Type: Article

References (31)

1. Buas M.F., Vaughan T.L. Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease. Seminars in Radiation Oncology 2013, 23:3-9.
2. Mathieu L.N., Kanarek N.F., Tsai H.L., et al. Age and sex differences in the incidence of esophageal adenocarcinoma: results from the Surveillance, Epidemiology, and End Results (SEER) Registry (1973-2008). Diseases of the Esophagus 2013, [accessed 10.03.14]. 10.1111/dote.12147.
3. Fitzgerald R.C., di Pietro M., Ragunath K., et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut 2014, 63:7-42.
4. Gatenby P.A., Ramus J.R., Caygill C.P., et al. Relevance of the detection of intestinal metaplasia in non-dysplastic columnar-lined oesophagus. Scandinavian Journal of Gastroenterology 2008, 43:524-530.
5. Hahn H.P., Blount P.L., Ayub K., et al. Intestinal differentiation in metaplastic, nongoblet columnar epithelium in the esophagus. American Journal of Surgical Pathology 2009, 33:1006-1015.
6. Ayanbule F., Belaguli N.S., Berger D.H. GATA factors in gastrointestinal malignancy. World Journal of Surgery 2011, 35:1757-1765.
7. Molkentin J.D. The zinc finger-containing transcription factors GATA-4, -5, and -6. Ubiquitously expressed regulators of tissue-specific gene expression. Journal of Biological Chemistry 2000, 275:38949-38952.
8. Jonckheere N., Vincent A., Franquet-Ansart H., et al. GATA-4/-6 and HNF-1/-4 families of transcription factors control the transcriptional regulation of the murine Muc5ac mucin during stomach development and in epithelial cancer cells. Biochimica et Biophysica Acta 2012, 1819:869-876.
9. Beuling E., Aronson B.E., Tran L.M., et al. GATA6 is required for proliferation, migration, secretory cell maturation, and gene expression in the mature mouse colon. Molecular and Cellular Biology 2012, 32:3392-3402.
10. Beuling E., Baffour-Awuah N.Y., Stapleton K.A., et al. GATA factors regulate proliferation, differentiation, and gene expression in small intestine of mature mice. Gastroenterology 2011, 140:1219-1229.
11. Kwei K.A., Bashyam M.D., Kao J., et al. Genomic profiling identifies GATA6 as a candidate oncogene amplified in pancreatobiliary cancer. PLoS Genetics 2008, 4:e1000081. [accessed 10.03.14].
12. Shureiqi I., Zuo X., Broaddus R., et al. The transcription factor GATA-6 is overexpressed in vivo and contributes to silencing 15-LOX-1 in vitro in human colon cancer. FASEB Journal 2007, 21:743-753.
13. Belaguli N.S., Aftab M., Rigi M., et al. GATA6 promotes colon cancer cell invasion by regulating urokinase plasminogen activator gene expression. Neoplasia 2010, 12:856-865.
14. Tian F., Li D., Chen J., et al. Aberrant expression of GATA binding protein 6 correlates with poor prognosis and promotes metastasis in cholangiocarcinoma. European Journal of Cancer 2013, 49:1771-1780.
15. Zhong Y., Wang Z., Fu B., et al. GATA6 activates Wnt signaling in pancreatic cancer by negatively regulating the Wnt antagonist Dickkopf-1. PLoS ONE 2011, 6:e22129. [accessed 10.03.14].
16. Chen W.B., Huang F.T., Zhuang Y.Y., et al. Silencing of GATA6 suppresses SW1990 pancreatic cancer cell growth in vitro and up-regulates reactive oxygen species. Digestive Diseases and Sciences 2013, 58:2518-2527.
17. Whissell G., Montagni E., Martinelli P., et al. The transcription factor GATA6 enables self-renewal of colon adenoma stem cells by repressing BMP gene expression. Nature Cell Biology 2014, 16:695-707.
18. Kimchi E.T., Posner M.C., Park J.O., et al. Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation. Cancer Research 2005, 65:3146-3154.
19. Haveri H., Westerholm-Ormio M., Lindfors K., et al. Transcription factors GATA-4 and GATA-6 in normal and neoplastic human gastrointestinal mucosa. BMC Gastroenterology 2008, 8:9. [accessed 10.03.14]. 10.1186/1471-230X-8-9.
20. Alvarez H., Opalinska J., Zhou L., et al. Widespread hypomethylation occurs early and synergizes with gene amplification during esophageal carcinogenesis. PLoS Genetics 2011, 7:e1001356. [accessed 10.03.14].
21. Lin L., Bass A.J., Lockwood W.W., et al. Activation of GATA binding protein 6 (GATA6) sustains oncogenic lineage-survival in esophageal adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:4251-4256.
22. Taubert H., Heidenreich C., Holzhausen H.J., et al. Expression of survivin detected by immunohistochemistry in the cytoplasm and in the nucleus is associated with prognosis of leiomyosarcoma and synovial sarcoma patients. BMC Cancer 2010, 10:65. 10.1186/1471-2407-10-65 [accessed 10.03.14].
23. Kaemmerer D., Peter L., Lupp A., et al. Comparing of IRS and Her2 as immunohistochemical scoring schemes in gastroenteropancreatic neuroendocrine tumors. International Journal of Clinical and Experimental Pathology 2012, 5:187-194.
24. Nicholson A.M., Graham T.A., Simpson A., et al. Barrett's metaplasia glands are clonal, contain multiple stem cells and share a common squamous progenitor. Gut 2012, 61:1380-1389.
25. Volkweis B.S., Gurski R.R., Meurer L., et al. Ki-67 antigen overexpression is associated with the metaplasia-adenocarcinoma sequence in Barrett's esophagus. Gastroenterology Research and Practice 2012, 10.1155/2012/639748 [accessed 10.03.14].
26. Tsuji S., Kawasaki Y., Furukawa S., et al. The miR-363-GATA6-Lgr5 pathway is critical for colorectal tumourigenesis. Nature Communications 2014, 5:3150.
27. Brabender J., Lord R.V., Danenberg K.D., et al. Increased c-myb mRNA expression in Barrett's esophagus and Barrett's-associated adenocarcinoma. Journal of Surgical Research 2001, 99:301-306.
28. Brabender J., Lord R.V., Metzger R., et al. Differential SPARC mRNA expression in Barrett's oesophagus. British Journal of Cancer 2003, 89:1508-1512.
29. Brabender J., Marjoram P., Lord R.V., et al. The molecular signature of normal squamous esophageal epithelium identifies the presence of a field effect and can discriminate between patients with Barrett's esophagus and patients with Barrett's-associated adenocarcinoma. Cancer Epidemiology, Biomarkers and Prevention 2005, 14:2113-2117.
30. Selaru F.M., Wang S., Yin J., et al. Beyond field effect: analysis of shrunken centroids in normal esophageal epithelia detects concomitant esophageal adenocarcinoma. Bioinformatics and Biology Insights 2007, 1:127-136.
31. Lord R.V., Salonga D., Danenberg K.D., et al. Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence. Journal of Gastrointestinal Surgery 2000, 4:135-142.